Dr. Louise Provencher is a surgeon-oncologist at the CHU de Québec-Laval University. She is also a clinical researcher at the Research Center of the CHU de Québec-Laval University, and clinical professor at the Laval University School of Medicine. Dr. Provencher is part of the research group of the Centre des Maladies du Sein of CHU de Québec-Laval University.

Dr. Provencher is a scientific committee member at the McPeak-Sirois research group and the CHU de Quebec leader for the National Surgical Adjuvant Breast and Bowel Project.

Using structured breast cancer data

The Centre des Maladies du Sein research team has a comprehensive database of all cancers diagnosed since 1974; more than 12,000 patients are listed. A database of biopsy data from 1999 is also available; data on more than 34,000 biopsies are listed. These databases allow quality publications that modify the management and follow-up of cancers and benign breast diseases.

Offer innovative treatments

The Centre des Maladies du Sein of CHU de Québec-Laval University research group is one of the largest in Canada offering innovative treatments for breast cancer. More than 50 clinical trials are active at all times and are offered to patients who consult at the clinic or are referred by clinics/hospitals in the area. These clinical trials provide access to innovative experimental medications and develop the expertise of our world-renowned oncologists.

Supporting quality of life

The Centre des Maladies du Sein of CHU de Québec-University research group is a pioneer in quality of life studies in breast cancer, from total mastectomy to partial mastectomy, to the use of the cooling cap to counteract hair loss, promoting physical activity to improve survivorship, including optimal preservation of the axillary lymph nodes. The research group is at the forefront of studies promoting quality of life despite the adverse effects of the disease on an individual’s life.

Hôpital Saint-Sacrement
1050, chemin Sainte-Foy
Centre des maladies du sein Deschênes-Fabia
Québec, Québec
Canada G1S 4L8
+1 418-682-7511
Louise.Provencher@chudequ... louise.provencher@crchude...

Latest news

74 entries « ‹ 1 of 8 › »

Ruel S, Ivers H, Savard MH, Gouin JP, Lemieux J, Provencher L, Caplette-Gingras A, Bastien C, Morin CM, Couture F, Savard J

Insomnia, immunity, and infections in cancer patients: Results from a longitudinal study.

Journal Article

Health Psychol, 2019, ISSN: 0278-6133.

Abstract | Links:

Humphries B, Lauzier S, Drolet M, Coyle D, Masse B, Provencher L, Robidoux A, Maunsell E

Wage losses among spouses of women with nonmetastatic breast cancer.

Journal Article

Cancer, 2019, ISSN: 0008-543X.

Abstract | Links:

Fehrenbacher L, Cecchini RS, Geyer CE Jr, Rastogi P, Costantino JP, Atkins JN, Crown JP, Polikoff J, Boileau JF, Provencher L, Stokoe C, Moore TD, Robidoux A, Flynn PJ, Borges VF, Albain KS, Swain SM, Paik S, Mamounas EP, Wolmark N

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.

Journal Article

J Clin Oncol, pp. JCO1901455, 2019, ISSN: 0732-183X.

Abstract | Links:

Leblond MA, Duchesne N, Provencher L, Hogue JC, Pinault S

Is contralateral breast ultrasound worthwhile in preoperative staging of breast cancer?

Journal Article

J Clin Ultrasound, 47 (4), pp. 195-200, 2019, ISSN: 0091-2751.

Abstract | Links:

von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wulfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr, KATHERINE Investigators

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

Journal Article

N Engl J Med, 380 (7), pp. 617-628, 2019, ISSN: 0028-4793.

Abstract | Links:

Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C, Boileau JF, Provencher L, Robidoux A, Rimawi M, McIntosh SA, Shalaby I, Stein RC, Thirlwell M, Dolling D, Morden J, Snowdon C, Perry S, Cornman C, Batten LM, Jeffs LK, Dodson A, Martins V, Modi A, Osborne CK, Pogue-Geile KL, Cheang MCU, Wolmark N, Julian TB, Fisher K, MacKenzie M, Wilcox M, Huang Bartlett C, Koehler M, Dowsett M, Bliss JM, Jacobs SA

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

Journal Article

J Clin Oncol, 37 (3), pp. 178-189, 2019, ISSN: 0732-183X.

Abstract | Links:

Corter AL, Speller B, McBain K, Wright FC, Quan ML, Kennedy E, Schmocker S, Baxter NN, RUBY Cohort Investigators

Evaluating A Multidisciplinary Cancer Conference Checklist: Practice Versus Perceptions.

Journal Article

J Multidiscip Healthc, 12 , pp. 883-891, 2019, ISSN: 1178-2390.

Abstract | Links:

Nabi H, Provencher L, Diorio C

RE: Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424).

Journal Article

J Natl Cancer Inst, 110 (12), pp. 1422-1423, 2018, ISSN: 0027-8874.

| Links:

Humphries B, Collins S, Guillaumie L, Lemieux J, Dionne A, Provencher L, Moisan J, Lauzier S

Women's Beliefs on Early Adherence to Adjuvant Endocrine Therapy for Breast Cancer: A Theory-Based Qualitative Study to Guide the Development of Community Pharmacist Interventions.

Journal Article

Pharmacy (Basel), 6 (2), 2018, ISSN: 2226-4787.

Abstract | Links:

Poirier E, Desbiens C, Poirier B, Boudreau D, Jacob S, Lemieux J, Doyle C, Diorio C, Hogue JC, Provencher L

Characteristics and long-term survival of patients diagnosed with pure tubular carcinoma of the breast.

Journal Article

J Surg Oncol, 117 (6), pp. 1137-1143, 2018, ISSN: 0022-4790.

Abstract | Links:

74 entries « ‹ 1 of 8 › »
Signaler des ajouts ou des modifications

Active projects

  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2023-04-30
  • Effect of environmental contaminants and methylome of breast adipose tissue on aromatase inhibitor efficacy in breast cancer, Subvention, Instituts de recherche en santé du Canada, Volet Projet: Concours pilotes, from 2016-07-01 to 2020-06-30
  • Omega-3 fatty acids in the prevention of breast cancer: role of obesity-related markers in breast tissues, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2018-10-01 to 2022-09-30
  • Pilot study of a community pharmacy-based program to enhance adherence to adjuvant endocrine therapy among breast, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2019-10-01 to 2022-02-28

Recently finished projects

  • A phase II randomized study evaluating the biological and clinical effects of the combination of palbociclib with letrozole as neoadjuvant therapy in women with estrogen receptor-positive primary breast cancer, Subvention, National Surgical Adjuvant Breast and Bowel Projects, from 2016-03-30 to 2019-03-31
  • A rando, placebo-contr, dble-blind ph. 3 study eval. safety and efficacy of the addition of velaparib + carboplatin vs the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early stage triple neg. breast cancer, Subvention, National Surgical Adjuvant Breast and Bowel Projects, from 2015-09-17 to 2019-03-31
  • Enhancing adherence to adjuvant endocrine therapy among breast cancer survivors: Pilot study of the S.O.I.E. program, Subvention, Instituts de recherche en santé du Canada, Volet Projet: Concours pilotes, from 2016-04-01 to 2018-04-30
  • Excellence in advanced cancer clinical trials initiative (the ExACCT Initiavive) , Subvention, Secrétariat Inter-Conseils (Canada) (CRSH, CRSNG, IRSC), Réseau de centres d'excellence (RCE), from 2017-01-18 to 2019-03-31
  • MA-12: Étude randomisée à double insu visant à comparer le tamoxifène avec un placebo chez les patientes atteintes d'un cancer du sein étendu aux ganglions lymphatiques et qui ont complété une chimiothérapie adjuvante ..., Subvention, L'Institut de recherche de la Société canadienne du cancer, Subvention de recherche, from 1997-04-01 to 2019-03-31
  • Mise à jour des connaissances en cancer du sein, Subvention, Pfizer Canada Inc., from 2018-01-24 to 2019-03-31
  • NSABP Breast Cancer Treatment Protocols, Subvention, National Institute of Health (USA), Subvention de recherche, from 1997-02-01 to 2019-01-31
  • Phase III study evaluating palbociclib (PD-0332991) a cyclin-dependent kinase(CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2- normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy (PENELOPE), Subvention, National Surgical Adjuvant Breast and Bowel Projects, from 2015-04-29 to 2019-03-31
  • Soutien à la banque de données clinique du Centre des maladies du sein, Subvention, Fondation du CHU de Québec, from 2018-07-16 to 2019-03-31
  • Soutien au service de kinésiologie, Subvention, Fondation du CHU de Québec, from 2018-07-20 to 2019-03-31
  • Soutien aux femmes nouvellement métastatiques d'un cancer du sein, Subvention, Fondation du cancer du sein du Québec, from 2015-06-01 to 2018-05-31
  • Towards better outcomes for young women with breast cancer : A pan-canadian collaborative - Reducing the bUrden of Breast cancer in Young women (RUBY), Subvention, Women's College Hospital, from 2016-03-10 to 2019-03-31
  • Utilisation de l'intelligence artificielle afin de maintenir automatiquement le registre national de suivi en concer du sein et du projet de recherche en cancer du sein associé, Subvention, Fondation du cancer du sein du Québec, from 2019-02-28 to 2019-03-31
Data provided by the Université Laval research projects registery